PainChek close to finding out if FDA approves its flagship app for use in dementia care
PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.
The Watchlist
Previous Video
Next Video
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online